北京若生智能科技有限公司
Drug Database
AR

artesunate (artesunate, Amivas)

✓ Approved

Amivas · 小分子 · 小分子

什么是 artesunate？

artesunate 是一种小分子，由Amivas研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)。

药物档案

商品名artesunate, Amivas
公司Amivas
药物类别小分子
给药途径Injectable (Others), Intravenous (IV)
状态Approved
来源： ClinicalTrials.gov, Amivas

治疗适应症

artesunate 针对 2 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsPlasmodium malariae infection✓ Approved
Infections and infestationsCytomegalovirus infectionPreclinical

相关研究文献

PubMedACS applied materials & interfaces2026-09-10

Functionalized Red Blood Cell Membrane Nanoplatform for Paclitaxel and Artesunate Induces Ferroptosis and Immunogenic Cell Death against Triple-Negative Breast Cancer.

Li Kaiming K, Zhu Xiaole X, Wu Haisi H, Li Jiang J et al.

Triple-negative breast cancer (TNBC) tends to exhibit extremely large rates of tumor recurrence and mortality owing to the absence on effective therapeutic targets. Paclitaxel is the chemotherapeutic drug of choice, but the clinical efficacy in TNBC is limited. In the present study, we developed a folic acid (FA)-modified red blood cell membrane biomimetic drug delivery system encapsulating both paclitaxel and artesunate (PA@LRM-FA) against TNBC, aimed at enhancing ferroptosis and promoting immunogenic cell death to improve paclitaxel efficacy. The morphology, particle size, zeta potential, particle stability, paclitaxel and artesunate loading capacity, and paclitaxel and artesunate encapsulation efficiency of the formulations were studied. Through a cellular assay, we discovered that PA@LRM-FA inhibited the 4T1 cell proliferation, induced ROS accumulation, and promoted ferroptosis and immunogenic cell death. In tumor-bearing mice, PA@LRM-FA effectively targeted tumor tissues for the delivery of paclitaxel and artesunate and significantly induced ferroptosis, promoting immunogenic cell death and active immune cells in 4T1 tumors, resulting in a marked inhibition of tumor growth. Taken together, this work demonstrated a feasible therapeutic approach to inhibit TNBC by enhancing tumor ferroptosis and immunogenic cell death through PA@LRM-FA delivery of paclitaxel and artesunate.

PMID 42717767
阅读全文 →
PubMedACS pharmacology & translational science2026-09-10

Bergenia ciliata Root Extract Attenuates Artesunate-Induced Hepatotoxicity via Dual Modulation of Oxidative Stress and Apoptotic Signaling: An In Vitro and In Vivo Study.

Jena Sudip Prasad SP, Evan Prince Sabina S

Artesunate (ART), a widely used antimalarial drug, has been associated with hepatotoxic effects when administered at supratherapeutic doses over prolonged durations. This study aimed to elucidate the biochemical and molecular mechanisms underlying ART-induced liver injury and to evaluate the hepatoprotective potential of Bergenia ciliata root extract (BCRE) as a cotreatment, using a combination of in vitro and in vivo approaches. B. ciliata was selected based on its well-documented antimalarial activity and hepatoprotective properties. In vitro cytotoxicity was assessed by determining the IC50 value, while in vivo hepatotoxicity was induced in an experimental animal model through supratherapeutic ART administration. ART-treated animals exhibited a significant elevation in hepatic enzyme levels, increased oxidative stress markers, pronounced histopathological damage, upregulation of the pro-apoptotic marker Caspase-3, and downregulation of the antiapoptotic marker Bcl-2, collectively indicating activation of the apoptotic pathway. Coadministration of BCRE significantly attenuated all of these biochemical, histopathological, and apoptotic alterations in a dose-dependent manner, with the high-dose BCRE group demonstrating a level of hepatoprotection comparable to the standard positive control, silymarin. These findings suggest that BCRE confers hepatoprotection against ART-induced liver injury through dual mechanisms: attenuation of oxidative stress and inhibition of apoptosis, supporting its potential as a safe and effective adjunct to ART-based antimalarial therapy.

PMID 42719850
阅读全文 →
PubMedCancer management and research2026-09-10

Thyroid Cancer in the Modern Era: From Molecular Landscape and Multimodal Diagnostics to Integrative Traditional Chinese Medicine-A Comprehensive Review.

Xiong Yingqi Y, Hu Yaxin Y, Wang Manya M, Xiong Xin X et al.

In recent decades, the global incidence of thyroid cancer has risen sharply mainly due to the high detection rate of papillary thyroid microcarcinoma and overdiagnosis, with its overall mortality staying steady. Classic pathogenic drivers encompass childhood radiation exposure, iodine disorder, and hallmark gene alterations including BRAF V600E, RET/PTC, RAS and PAX8/PPARγ. Modern multimodal diagnostic systems integrating artificial intelligence-assisted high-resolution ultrasound, Thyroseq-V2, Afirma, circulating tumor DNA detection and refined pathological examination achieve precise preoperative stratification. Aberrant activation of MAPK/ERK, PI3K/AKT and Wnt/β-catenin cascades, coupled with an immune-suppressive tumor microenvironment dominated by M2-type tumor-associated macrophages, regulatory T cells and PD-L1 overexpression, drives thyroid cancer progression and dedifferentiation. Current comprehensive integrated therapeutic strategies cover robotic surgery, radioactive iodine ablation, external radiotherapy, molecular targeted drugs (sorafenib, lenvatinib, vemurafenib combined with trametinib) and novel immunotherapy. Traditional Chinese Medicine (TCM), based on the TCM pathogenesis of liver qi stagnation, phlegm-blood stasis and qi-blood deficiency for goiter, serves as an adjuvant therapy for thyroid cancer. Active ingredients such as honokiol, artesunate, ginsenoside Rg3, astragalus polysaccharide and curcumin can suppress tumor proliferation, reshape anti-tumor immunity and inhibit metastasis via regulating reactive oxygen species, PI3K/AKT pathway, epithelial-mesenchymal transition and matrix metalloproteinases. Existing clinical observations confirm that TCM can relieve clinical discomfort, improve life quality and lower recurrence risk when combined with conventional radioiodine or anti-tumor treatment. However, the clinical application of TCM for thyroid cancer is greatly restricted by insufficient syndrome differentiation standardization, low-quality clinical evidence and unclear herbal safety risks. Most available studies are small-sample retrospective analyses lacking large-scale, multicenter randomized controlled trials to verify efficacy and safety. Future research should focus on standardized clinical trial design, in-depth pharmacological mechanism exploration, and construction of standardized thyroid cancer integrative diagnosis and treatment regimens combining Western precision therapy and TCM adjuvant intervention, to clarify the definite positioning of TCM in whole-course thyroid cancer management.

PMID 42719379
阅读全文 →
PubMedDrug delivery2026-09-04

An injectable hydrogel for localized sustained release of artesunate in postoperative fibrosis prevention after glaucoma filtration surgery.

Tan Guangshuang G, Zhang Lusi L, Wu Tong T, Liu Jingyuan J et al.

Glaucoma filtration surgery (GFS) is the definitive treatment for reducing intraocular pressure in patients with refractory glaucoma. However, postoperative scarring of the filtration tract is a major cause of surgical failure. Although artesunate (ART) exhibits significant antifibrotic efficacy, its clinical application is severely limited by poor solubility and a short half-life. This study designed and developed a new injectable hydrogel cross-linked by collagen and four-armed polyethylene glycol N-hydroxysuccinimide encapsulating ART (C-P@ART) to overcome the limitations of ART in ocular antifibrotic therapy and extensively examined its underlying mechanisms. Stable three-dimensional network structure, excellent biocompatibility, and sustained drug release characteristics of C-P@ART were validated through FTIR, rheological analysis, endotoxin-testing, scanning electron microscope (SEM), and in vitro and in vivo release assays. In a TGF-β1-induced fibroblast fibrosis model, C-P@ART significantly inhibited α-SMA expression concentration-dependently and exerted antifibrotic effects through dual regulation of TGF-β1/SMAD and PI3K/Akt pathways. Subsequently, we evaluated its antifibrotic efficacy in the rabbit GFS model, where the C-P@ART treatment group exhibited a significant reduction in postoperative collagen deposition and α-SMA-positive expression compared to the control group. C-P@ART inhibited NF-κB pathway activation and reduced inflammatory cell infiltration. In conclusion, these findings demonstrated that C-P@ART synergistically mitigates fibrosis and inflammation through sustained ART release, providing an innovative therapeutic strategy to enhance GFS outcomes.

PMID 42695923
阅读全文 →
PubMedACS nano2026-09-03

Inflammation Targeting Lymphocyte Apoptotic Body Hybrid Nanovesicles Alleviate Ovarian Inflammation in Polycystic Ovary Syndrome.

Shen Xuezhi X, Yu Qifan Q, Shen Yanhong Y, Zhang Bufan B et al.

Sustained inflammation localized in the ovarian microenvironment has been implicated as a key pathophysiological driver of polycystic ovary syndrome (PCOS), primarily disrupting normal folliculogenesis and arresting ovulation. Current therapies generally fail to address this underlying pathology due to their limitation in precisely targeting or modulating the ovarian immune microenvironment. Consequently, inflammation-induced tissue damage remains largely unresolved. To overcome this limitation, we developed a biomimetic hybrid nanovesicle termed TLAB@ATS. This platform combines anti-inflammatory T cell-derived apoptotic bodies (AB) with reactive oxygen species (ROS)-responsive thioketal (TK)-linked lipids for the targeted delivery of artesunate (ATS). Leveraging the natural homing ability of AB, TLAB@ATS specifically accumulates in ovarian inflammation, where elevated ROS levels induce cleavage of the TK linkers to trigger the on-demand release of ATS. We found that TLAB@ATS suppresses the expression of pro-inflammatory cytokines, significantly reduces ovarian oxidative stress and inflammatory immune cell infiltration, and thereby restores endocrine balance, alleviates ovarian inflammatory infiltration, and promotes normal folliculogenesis. Collectively, this tailored nanoplatform provides a targeted approach for alleviating ovarian inflammation in PCOS.

PMID 42689706
阅读全文 →
PubMedThe American journal of tropical medicine and hygiene2026-09-01

How Should We Treat Severe Malaria in the Setting of Artemisinin Partial Resistance?

Rosenthal Philip J PJ, Kamya Moses R MR, Namazzi Ruth R, John Chandy C CC

Artemisinin partial resistance (ART-R) threatens the control of falciparum malaria, but its impact on the treatment of severe malaria has been unclear. Two recent studies in Uganda have considered associations between PfK13 mutations linked to ART-R and treatment outcomes in children hospitalized with complicated or severe malaria and treated with intravenous artesunate. Children infected with ART-R parasites experienced delayed parasite clearance compared to those infected with drug-sensitive parasites. However, clinical outcomes, including mortality, length of hospital stay, incidence of subsequent febrile illness, and incidence of readmission did not differ between children infected with ART-R or drug-sensitive parasites. Therefore, at present treatment with intravenous artesunate should remain the standard-of-care to treat severe malaria in sub-Saharan Africa, even in the setting of ART-R, although continued study of treatment efficacy is warranted.

PMID 42679801
阅读全文 →

注册免费账户还可查看另外 4195 篇文献

免费注册查看全部文献 →

了解更多artesunate